Host
Publication/Presentation Date
1-15-2019
Abstract
PURPOSE: Heritable genetic variations can affect the inflammatory tumor microenvironment, which can ultimately affect cancer susceptibility and clinical outcomes. Recent evidence indicates that IDO2, a positive modifier in inflammatory disease models, is frequently upregulated in pancreatic ductal adenocarcinoma (PDAC). A unique feature of
RESULTS: PDAC development was notably decreased in the
CONCLUSIONS: The results of this study provide genetic support for IDO2 as a contributing factor in PDAC development and argue that
Volume
25
Issue
2
First Page
724
Last Page
734
ISSN
1557-3265
Published In/Presented At
Nevler, A., Muller, A. J., Sutanto-Ward, E., DuHadaway, J. B., Nagatomo, K., Londin, E., O'Hayer, K., Cozzitorto, J. A., Lavu, H., Yeo, T. P., Curtis, M., Villatoro, T., Leiby, B. E., Mandik-Nayak, L., Winter, J. M., Yeo, C. J., Prendergast, G. C., & Brody, J. R. (2019). Host IDO2 Gene Status Influences Tumor Progression and Radiotherapy Response in KRAS-Driven Sporadic Pancreatic Cancers. Clinical cancer research : an official journal of the American Association for Cancer Research, 25(2), 724–734. https://doi.org/10.1158/1078-0432.CCR-18-0814
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
30266763
Department(s)
Administration and Leadership
Document Type
Article